EGFR L858R

EGFR 19Del and 21L858R mutations are associated with distinct expression patterns of VEGFR1 and CD34, which may underlie differential responses to anti-angiogenic therapy and inform future combination treatment strategies.

P2, N=520, Recruiting, Janssen Research & Development, LLC | Trial completion date: Aug 2027 --> Aug 2028

P2, N=84, Not yet recruiting, Hebei Medical University Fourth Hospital

Its robustness was further validated using clinical blood samples, enabling sensitive detection of low-abundance L858R mutations. These results demonstrate that the integration of programmable target recognition, efficient signal amplification, and fluorescence readout provides a promising platform for SNP analysis in liquid biopsy, supporting precision diagnosis and treatment monitoring in NSCLC.

Survival does not appear to be influenced by cVAF either. The identification and structural characterization of novel compound EGFR uncommon mutations may explain the benefit experienced by patients.

Disruption of glycosylation at N361, located near the ligand binding and dimerization regions, created a dominant negative form of EGFR, which non-productively co-localized with HER2, resulting in a blockage in proliferation. These findings underline the critical relevance of post-translational glycosylation modifications on EGFR function.

P1, N=56, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting

P2, N=64, Recruiting, Chinese University of Hong Kong | Not yet recruiting --> Recruiting

P2, N=46, Not yet recruiting, Massachusetts General Hospital

Of these, two patients were treated with a third-generation TKI: 1 achieved SD and the other achieved partial response (PR). This integrated retrospective analysis suggests that third-generation EGFR-TKIs may provide disease control (PR/SD) and prolonged PFS in a subset of NSCLC patients harboring uncommon EGFR p.L747P or p.L747S mutations, particularly those with co-existing sensitizing mutations or central nervous system metastases (CNS).

With a primary EGFR p.L858R-mutant NSCLC, osimertinib was administered, resulting in a partial response within 10 months. In addition, given the synchronous primary pancreatic adenocarcinoma, germline testing was performed, revealing a CDKN2A p.I49T variant consistent with melanoma-pancreatic cancer syndrome, prompting comprehensive cancer surveillance and familial testing. This case illustrates how ctDNA testing enabled a comprehensive evaluation by clarifying the diagnosis, identifying actionable biomarkers, and facilitating genetic risk assessment, ultimately having a significant impact on the patient's clinical management.

P2, N=367, Active, not recruiting, AstraZeneca | Trial completion date: May 2025 --> Dec 2026